|
WO2021011404A1
|
|
Therapeutic protein formulations comprising antibodies and uses thereof
|
|
WO2021007107A1
|
|
Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria
|
|
WO2020210691A1
|
|
Method of treating and preventing bone and joint infections
|
|
WO2020206327A1
|
|
Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum
|
|
WO2020198073A1
|
|
Method of treating infective endocarditis
|
|
US2020157160A1
|
|
Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
|
|
WO2020046747A1
|
|
Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
|
|
CA3095473A1
|
|
Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
|
|
KR20210024005A
|
|
Lysine and its derivatives for resensitizing Staphylococcus aureus and Gram-positive bacteria to antibiotics
|
|
KR20210005027A
|
|
Antimicrobial Bacteriophage Induced Polypeptide and Its Use Against Gram-negative Bacteria
|
|
AU2019245369A1
|
|
Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
|
|
CA3092109A1
|
|
Modified plyss2 lysins and uses thereof
|
|
US2021085758A1
|
|
Identification of lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa
|
|
WO2019014260A2
|
|
Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
|
|
MX2018013372A
|
|
Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides.
|
|
AU2016324307A1
|
|
Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
|
|
CA2938726A1
|
|
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
US2017189529A1
|
|
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
MX2015012397A
|
|
Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy.
|
|
AU2013259427A1
|
|
Biofilm prevention, disruption and treatment with bacteriophage lysin
|
